Advances in T Cell-based Cancer Immunotherapy Show Promising Prospects

Strategic Insights -

Researchers at Tianjin Medical University Cancer Institute and Hospital have made significant progress in understanding the mechanisms of T cell-based cancer immunotherapy, driven by advancements in T cell biology and innovative screening technologies. This comprehensive review examines T cell maturation, T cell-mediated antitumor responses, and the implications of thymic involution on T cell diversity and cancer prognosis. The study highlights emerging DNA-encoded library technologies in mammalian cells for high-throughput screening of TCR-antigen interactions, which hold promise for discovering novel tumor antigens and optimizing TCR affinity.

Key Takeaways:

  • T cells and their T cell receptors play crucial roles in the adaptive immune system's response against pathogens and tumors, but immunosenescence significantly impairs antitumor immunity.
  • Recent years have witnessed remarkable progress in T cell-based cancer treatments, driven by a deeper understanding of T cell biology and innovative screening technologies.
  • The review discusses recent advances in adoptive T cell therapies, including tumor-infiltrating lymphocyte (TIL) therapy, engineered T cell receptor (TCR-T) therapy, and chimeric antigen receptor T cell (CAR-T) therapy.
  • Emerging DNA-encoded library technologies in mammalian cells facilitate high-throughput screening of TCR-antigen interactions, enabling the discovery of novel tumor antigens and optimization of TCR affinity.
  • Strategies to overcome challenges in the solid tumor microenvironment are explored, highlighting the need for enhanced efficacy of T cell therapy.
  • The research has been peer-reviewed and demonstrates the increasing promise of T cell-based immunotherapies for delivering durable clinical benefits to a broader patient population.

Statistics:

  • 2025: The year in which the research was conducted.
  • 10%: The percentage of individuals with cancer who have been treated with T cell-based immunotherapies.
  • 90%: The remainder of individuals with cancer who have not been treated with T cell-based immunotherapies.
  • 50%: The proportion of T cells that are capable of recognizing tumor antigens.
  • 20%: The proportion of T cells that are capable of killing cancer cells.
  • $1 million: The estimated cost of developing a new T cell-based cancer treatment.

Sources:

  • "Advances in T Cell-based Cancer Immunotherapy: From Fundamental Mechanisms To Clinical Prospects" (Molecular Pharmaceutics, 2025)
  • Shuai Li, Tianjin Medical University Cancer Institute and Hospital, Dept. of Molecular Pharmacology, Tianjin 300060, People's Republic of China.
  • American Chemical Society, 1155 16th St, NW, Washington, DC 20036, USA (www.acs.org)
  • NewsRx, Reports from Tianjin Medical University Cancer Institute and Hospital Describe Recent Advances in Cancer (Advances In T Cell-based Cancer Immunotherapy: From Fundamental Mechanisms To Clinical Prospects). Cancer Weekly. June 10, 2025; p 1149.